Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
20 enrolled 12 charts
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
18 enrolled 12 charts
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
6 enrolled 12 charts
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
23 enrolled 11 charts
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Phase 1 Completed
41 enrolled
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Phase 1 Completed
68 enrolled
Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor
Completed
19 enrolled
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
Phase 1 Completed
60 enrolled
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Phase 3 Completed
130 enrolled 9 charts
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
Phase 2 Completed
70 enrolled
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Phase 1 Completed
20 enrolled
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Phase 1 Completed
60 enrolled
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment
Phase 2 Completed
77 enrolled
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
Phase 1 Completed
25 enrolled
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Phase 2 Completed
200 enrolled
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
Phase 2 Completed
30 enrolled
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
Phase 1 Completed
30 enrolled
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
Phase 1 Completed
70 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Phase 1 Completed
30 enrolled
Prevention of Methotrexate Induced Nephrotoxicity and Prolonged Drug Elimination Time With 12 Hours Prehydration
Phase NA Completed
47 enrolled
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Phase 1 Completed
26 enrolled
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Phase 1 Completed
28 enrolled